paperBiotech

Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy

Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy

publishedDate Venue iScience

Source-permitted summary

Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy

SourceCell Press

AI Reading Notes

Core signal

Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.

Core signal
Application of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy
Field context
Diagnostics and Biomarkers
People and labs
Not stated in the reviewed source.
Why it matters
Recent source-backed research output for AISci Stage A browsing.
Limits to check
AISci rank score does not assess scientific quality or citation impact.

Publication facts

Date
Jul 16, 2026SourceCell Press
Venue
iScienceSourceCell Press
Open access
openSourceCell Press

External IDs

Author order

No reviewed author edge is attached to this output.

Organizations

No source-confirmed author affiliation is attached.

Related events

Topics

Relationship evidence

Timeline

  1. paperApplication of Epigenetic biomarkers in the precision medicine for sepsis-induced acute lung injury: From risk stratification to targeted therapy